Drug intelligence / Profile preview

CBM-CD20

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**CBM-CD20** is an autologous CAR-T cell therapy targeting CD20, developed by Cellular Biomedicine Group for relapsed/refractory B-cell lymphomas, particularly in patients who have progressed after CD19 CAR-T therapy. It uses patient-derived T cells engineered to express a chimeric antigen receptor specific for CD20, enabling targeted killing of CD20-positive malignant B cells via T-cell activation, proliferation, and cytotoxicity. Phase IIa results showed activity in diffuse large B-cell lymphoma (DLBCL) and other advanced B-cell non-Hodgkin lymphomas, with ongoing trials evaluating safety and efficacy in CD19 CAR-T relapsed settings.

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on CBM-CD20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBM-CD20.

Explore the full profile